ERBB2 and breast cancer: Our lab has previously shown that HER4 cleavage and nuclear translocation mediates acquired resistance to trastuzumab; and nuclear HER4 but not cytoplasmic HER4 is associated with poor outcome in HER2-positive breast cancer [40].